Development and Preliminary Testing of the Withdrawal Assessment Tool-Alpha 2 Agonist: An Assessment Instrument for Monitoring Iatrogenic Withdrawal Symptoms in Children Receiving an Alpha-2 Agonist
Acutely ill children receiving sedation with an A2A for more than 5 days may develop physiologic dependence, requiring gradual dosing reductions. While further psychometric testing is advised, the WAT-A2A provides an objective instrument to help clinicians quantify dexmedetomidine withdrawal symptoms in acutely ill children may facilitate A2A weaning and limit unnecessary variation in practice.
Authors
- Martha A. Q. Curley (ORCID: https://orcid.org/0000-0001-5228-6694)
- Jean C. Solodiuk (ORCID: https://orcid.org/0000-0003-2808-1853)
- Christine Greco (ORCID: https://orcid.org/0000-0002-9318-1159)
- Carolina Donado (ORCID: https://orcid.org/0000-0003-4345-9201)
- John Hayes
- Lia Wickerham
- Lindsay Goodyear
- Rachel E. Mortell
Institutions
- Center for Pain and the Brain (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Pediatric Critical Care Medicine
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1097/pcc.0000000000003645
- Citations
- 4
- Primary Topic
- Intensive Care Unit Cognitive Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.69